Oscotec: Litigation filed (management dispute)
Management dispute litigation filed following application for permission to convene general meeting of shareholders
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Osstem Implant's stock price edged lower due to a management dispute and institutional selling, despite its biotech pipeline.
Following the disclosure of a management dispute lawsuit, the stock faced downward pressure as institutions sold 15,733 shares. Despite IBK Securities' positive outlook with a target price of ₩67,000, the stock closed lower due to short-term uncertainty surrounding the dispute and institutional selling.
- 09.18 ★★ [Amended] Report on Large Shareholdings (General)
- 09.17 ★★ Report on major shareholding (abbreviated)
- 09.17 ★★ Large Shareholding Report (General)
- 09.04 ★★★ Termination of business following receipt of Phase 1a/1b clinical trial results for Alzheimer's treatment and subsequent technology transfer
- 09.01 ★★ Large Shareholding Report (General)
For information only. Not investment advice.